Scope and Claims Analysis for US Patent 11,874,283: ET-1 Antagonist Methods and Biomarker Monitoring for IgA Nephropathy
US 11,874,283 claims methods tied to IgA nephropathy patient stratification by elevated endothelin-1 (ET-1) and use of an ET-1 antagonist as the sole active ingredient. The independent claim 1 is directed to (i) treating IgA nephropathy in an ET-1-high mammal and (ii) administering a pharmaceutical composition containing only one ET-1 antagonist selected from a defined list. Dependent claims narrow to specific antagonists (ambrisentan, atrasentan) and a kidney-local infusion route. Claim 4 expands to a dual-purpose regimen: monitoring treatment effectiveness using ET-1-associated biomarkers and separately assessing broader kidney biomarker response (ppET-1, pET-1, BIG ET-1, ECE, cystatin C, creatinine, and ACR), with dose adjustment based on biomarker results.
What is US 11,874,283 claim scope for treating IgA nephropathy with an ET-1 antagonist?
Core coverage (Claim 1, independent):
A method of treating IgA nephropathy in a mammalian subject that is (a) diagnosed at a qualified medical center and (b) shown to have increased ET-1 levels relative to controls without IgA nephropathy. Treatment is performed by administering an “effective amount” of a pharmaceutical composition with:
- Active ingredient: consists of an ET-1 antagonist
- Carrier: pharmaceutically acceptable carrier
- Sole active ingredient requirement: the ET-1 antagonist is the only active ingredient in the composition
- Antagonist species limitation: ET-1 antagonist is selected from: sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan, tezosentan
Meaning of the “ET-1-high” condition (limitation effect):
The method is not framed as a general IgA nephropathy treatment irrespective of biomarker status. It requires that the patient be diagnosed with IgA nephropathy and have an increased ET-1 level “compared to ET-1 levels in those without IgA nephropathy.” This is a clinical stratification limitation, which can narrow infringement to ET-1-elevated populations or require proof that the accused method includes the ET-1 increase selection step.
Meaning of “ET-1 antagonist” and the closed list:
The claim does not broadly cover “any endothelin antagonist.” It is tethered to a closed group by naming specific agents and one peptide (BQ-123). Practically, infringement depends on whether the accused composition contains one of the listed ET-1 antagonists as the only active agent.
Meaning of “only active ingredient” (composition limitation):
The claim requires the pharmaceutical composition to have the ET-1 antagonist as the only active ingredient. That typically excludes combination products where a second intentional active component is present in the same pharmaceutical composition. It also creates design-around pressure: co-formulations or combination therapy where multiple active ingredients are part of the same composition can avoid this claim.
Claim 1 is process-based with a specific composition requirement:
A practical reading is that infringement can attach to the clinician’s method and the administered drug product, not only to manufacturing. The composition requirement makes the specific product profile relevant in enforcement.
Claim 1 key operative elements (in infringement-style terms)
- Patient: mammalian subject with IgA nephropathy diagnosed at a qualified medical center
- Biomarker: subject has increased ET-1 vs a control group without IgA nephropathy
- Treatment: administer effective amount
- Drug product: pharmaceutical composition comprising
- active ingredient consisting of an ET-1 antagonist
- pharmaceutically acceptable carrier
- and ET-1 antagonist is the only active ingredient
- Antagonist selection: one of sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan, tezosentan
Which dependent claims narrow US 11,874,283 to specific drugs and administration routes?
Claim 2 (ambrisentan):
If the ET-1 antagonist is ambrisentan, the method falls within the narrower dependent claim. This is the tightest “specific drug” narrowing within the listed antagonists.
Claim 3 and Claim 5 (local kidney infusion):
- Claim 3 depends from claim 1 and recites that the ET-1 antagonist is administered by local infusion into a kidney.
- Claim 5 is similar but is dependent from claim 4 (monitoring method) and similarly limits route.
Route limitation matters because many ET-1 antagonists are administered systemically. If an accused protocol uses systemic dosing, these route-dependent claims likely do not read on it. If an accused protocol does local renal infusion, route-dependent infringement risk increases.
Claim 6 (atrasentan):
If the ET-1 antagonist is atrasentan, claim 6 provides an additional narrower claim coverage.
Design-around implications from dependent claims:
- Switching to an ET-1 antagonist outside the named list can avoid claims 1/2/6.
- Using an ET-1 antagonist from the list but in a combination product with another active ingredient in the same pharmaceutical composition can aim to defeat the “only active ingredient” limitation.
- Using systemic delivery rather than local kidney infusion can reduce risk under route-dependent claims 3/5 (though claim 1 still can cover treatment regardless of route, unless route becomes implicated by other factors in enforcement).
What is US 11,874,283 claim scope for monitoring and biomarker-based dose adjustment?
Core coverage (Claim 4, independent):
Claim 4 claims a monitoring method for effectiveness of an IgA nephropathy treatment that is also linked to increased ET-1. It recites:
- Step (a): Administer to a subject with ET-1-linked IgA nephropathy a pharmaceutical composition containing:
- only active ingredient: an ET-1 antagonist selected from sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan, tezosentan
- Step (b): Measure an ET-1-associated biomarker in a first sample prior to treatment initiation
- Step (c): Compare first measurement to a control subject
- Step (d): Measure the ET-1-associated biomarker again in a second sample after treatment initiation
- Step (e): Determine effectiveness based on the after-vs-before result relative to the control comparison, specifically comparing ET-1 levels as the ET-1-associated biomarker, and adjust the amount of ET-1 inhibitor administration accordingly
- Separately determine effect using one or more ET-1-associated biomarkers selected from the set:
- ppET-1
- pET-1
- BIG ET-1
- endothelin converting enzyme (ECE)
- cystatin C
- creatinine
- albumin-creatinine ratio (ACR)
and adjust ET-1 inhibitor amount based on those biomarker results
Important drafting feature: “ET-1-associated biomarker”
Claim 4 first calls for an ET-1-associated biomarker and then states effectiveness is determined “as to the level of ET-1 as the ET-1-associated biomarker.” This indicates the method includes measurement of ET-1 itself at least as one pathway. It then adds a second biomarker selection set (ppET-1, pET-1, etc.) and requires “separately determining” effect using biomarker(s) from that set.
Control comparison step (b to c):
Claim 4 requires comparison to a control subject. That may affect how a monitoring workflow is implemented and what documentation is needed for enforcement.
Dose adjustment requirement:
The claim’s “adjusting the amount of ET-1 inhibitor administration based thereon” is not optional. Even if biomarker readings indicate response, the claimed method includes the act of adjusting dosing.
Separate determination across two biomarker classes:
Claim 4 appears to require two separate assessments:
- Effectiveness based on ET-1 level change (relative to before and compared to control)
- Separate assessment based on chosen biomarker(s) from the extended list (including kidney function markers and ACR), also with dose adjustment
This expands scope beyond just monitoring ET-1 response; it ties the adjustment to renal-related biomarkers that can be used to titrate therapy.
Claim 4 key operative elements
- Same qualifying patient concept as claim 1: IgA nephropathy linked to increased ET-1 and diagnosed at qualified medical center
- Administer ET-1 antagonist pharmaceutical composition with:
- only active ingredient = ET-1 antagonist
- ET-1 antagonist in the closed list
- Monitoring workflow includes:
- pre-dose baseline measurement of ET-1-associated biomarker
- post-initiation repeat measurement
- compare to control subject
- determine effectiveness using ET-1 levels
- adjust ET-1 inhibitor dose
- separately determine effect using at least one chosen biomarker from the second list and adjust dose
How does the patent landscape likely interact with ET-1 antagonists already in nephrology pipelines?
Claim 1 and 4 are limited to a closed list of ET-1 antagonists. That list includes both branded small molecules and at least one peptide. In practice, this creates a relatively clear infringement map by drug identity:
- Ambrisentan is singled out in claim 2
- Atrasentan is singled out in claim 6
- Local renal infusion is singled out in claims 3/5
- Remaining list members (sitaxentan, bosentan, tezosentan, BQ-123) are covered through the independent claims 1/4
Landscape logic for business risk:
- The closer a competitor’s protocol is to “ET-1-high IgA nephropathy,” “drug from the named list,” “ET-1 antagonist only (no second active),” and “use of biomarker-based titration,” the more the claim set is implicated.
- If competitors use systemic dosing but still administer one of the named antagonists alone, claim 1 remains in play.
- If competitors dose-titrate based on kidney biomarkers rather than ET-1 or do not perform the required baseline-and-control comparisons, claim 4’s monitoring and adjustment elements become harder to map.
Claim design suggests two enforcement pressure points:
- Patient selection by ET-1 elevation
- Therapeutic decision protocol that adjusts dose based on ET-1-linked biomarker dynamics
These features can be used in litigation to argue method infringement tied to clinical protocols and to captured data.
What does US 11,874,283 protect that generic or biosimilar entrants could avoid?
Potential escape routes implied by the claim language:
-
Combination therapy in the same composition
The “only active ingredient” requirement can be used to argue non-infringement if an accused regimen uses a second active ingredient in the same administered pharmaceutical composition (not merely concurrently given as separate dosage forms, depending on enforcement theory). If the clinical regimen uses multiple actives, claim 1/4 may not read on the composition requirement.
-
Non-listed endothelin antagonists
The claim is restricted to the named ET-1 antagonists. Any ET-1 antagonist outside the list (even if pharmacologically similar) is outside the claim’s explicit coverage.
-
Avoiding the monitoring method elements
Claim 4 requires:
- pre-treatment baseline measurement
- post-treatment measurement
- comparison to a control subject
- dose adjustment based on the measured results
- and separate determination for biomarker(s) from the listed set
If an accused method does not adjust dose based on these measurements or does not compare to control as claimed, claim 4 risk drops.
-
Avoiding local kidney infusion
Claims 3/5 require local infusion into the kidney. Systemic administration avoids these dependent claims, leaving claim 1 as the remaining coverage for treatment methods (if the other limitations still match).
Key claim-to-implementation mapping (quick infringement checklist)
| Element |
Claim 1 treatment |
Claim 4 monitoring |
Practical match to clinical protocol |
| IgA nephropathy diagnosed at qualified center |
Yes |
Yes |
Trial/clinical program documentation |
| ET-1 increased vs controls without IgA nephropathy |
Yes |
Yes |
Inclusion criteria or stratification method |
| Drug composition contains only ET-1 antagonist + carrier |
Yes |
Yes |
Product formulation and labeling |
| ET-1 antagonist identity |
Closed list |
Closed list |
Drug selection |
| Route local kidney infusion |
Only in claim 3 |
Only in claim 5 |
Administration method |
| Pre-dose and post-dose biomarker measurement |
Not required |
Yes |
Monitoring schedule |
| Control comparison |
Not required |
Yes |
Statistical/clinical control selection |
| Dose adjustment based on biomarker results |
Not required |
Yes |
Titration algorithm |
| Biomarker types |
ET-1 level concept |
ET-1 plus selected biomarker set |
Assay panel and endpoints |
What is the likely practical “scope window” across antagonists and protocols?
Highest-scope coverage:
- Clinical protocols treating ET-1-high IgA nephropathy with a single-agent ET-1 antagonist from the named list, with ET-1 biomarker monitoring and titration of dose based on ET-1-associated biomarker dynamics. This is the strongest overlap between the therapeutic and monitoring claim families (claims 1 and 4).
Moderate-scope coverage:
- Single-agent treatment with one of the named ET-1 antagonists in an ET-1-high IgA nephropathy population without the specific monitoring and titration workflow. This implicates claim 1 but not necessarily claim 4.
Lower-scope coverage:
- Protocols using systemic dosing only: claim 3/5 likely fall away, but claim 1/4 treatment and monitoring remain unless route is central to other limitations.
Key Takeaways
- US 11,874,283 covers ET-1-high IgA nephropathy treatment using a single active ingredient ET-1 antagonist from a closed list (sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan, tezosentan).
- Claim 1 is treatment; claim 4 is monitoring with baseline-to-post biomarker comparisons, control comparison, and dose adjustment.
- Dependent claims narrow to ambrisentan (claim 2), atrasentan (claim 6), and local kidney infusion (claims 3 and 5).
- The “only active ingredient” and closed list of antagonists create the main design-around levers; the biomarker/titration requirements create the main vulnerability for monitoring-based workflows.
FAQs
1. Does US 11,874,283 require measuring ET-1 before dosing?
Claim 4 requires a pre-treatment measurement of an ET-1-associated biomarker; claim 1 is framed as a method in an ET-1-high subject, with the elevated ET-1 requirement tied to patient status.
2. Can a combination drug regimen avoid US 11,874,283?
The claims require the ET-1 antagonist to be the only active ingredient in the administered pharmaceutical composition, so introducing another active ingredient in the same composition can move outside the claimed composition scope.
3. Is local renal infusion mandatory to infringe US 11,874,283?
No. Local infusion is required only for the dependent claims (claims 3 and 5). Claim 1 and the non-route aspects of claim 4 do not require local infusion.
4. Which biomarkers are explicitly listed for monitoring in US 11,874,283?
The biomarker list in claim 4 includes ppET-1, pET-1, BIG ET-1, ECE, cystatin C, creatinine, and ACR, in addition to the ET-1 level concept.
5. Are all endothelin receptor antagonists covered under US 11,874,283?
No. The claims cover only the ET-1 antagonists named in the closed list (including ambrisentan and atrasentan).
References
No sources cited because the prompt provides only the claim text and does not provide patent bibliographic data, prosecution history, or any external record for US 11,874,283 (e.g., publication number, assignee, file dates, related applications, or cited art).
